Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2013, Article ID 378657, 33 pages
http://dx.doi.org/10.1155/2013/378657
Review Article

Herbal Therapies for Type 2 Diabetes Mellitus: Chemistry, Biology, and Potential Application of Selected Plants and Compounds

1Department of Veterinary Medicine, National Chung Hsing University, Taichung 402, Taiwan
2Department of Life Science, National Taiwan Normal University, Taipei 116, Taiwan
3Institute of Chemistry, University of the Philippines, Diliman, Quezon City 1100, Philippines
4Agricultural Biotechnology Research Center, Academia Sinica, No. 128, Academia Sinica Road, Section 2, Nankang, Taipei 115, Taiwan
5Graduate Institute of Immunology, China Medical University, Taichung 404, Taiwan
6Center for Neuropsychiatry, China Medical University Hospital, Taichung 404, Taiwan
7Institute of Pharmacology, Yang-Ming University, Taipei 112, Taiwan
8Institute of Zoology, National Taiwan University, Taipei 106, Taiwan
9Department of Life Sciences, National Chung Hsing University, Taichung 402, Taiwan

Received 6 February 2013; Accepted 11 March 2013

Academic Editor: William C. Cho

Copyright © 2013 Cicero L. T. Chang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. E. Shaw, R. A. Sicree, and P. Z. Zimmet, “Global estimates of the prevalence of diabetes for 2010 and 2030,” Diabetes Research and Clinical Practice, vol. 87, no. 1, pp. 4–14, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. J. P. Boyle, M. M. Engelgau, T. J. Thompson et al., “Estimating prevalence of type 1 and type 2 diabetes in a population of African Americans with diabetes mellitus,” American Journal of Epidemiology, vol. 149, no. 1, pp. 55–63, 1999. View at Google Scholar · View at Scopus
  3. A. S. Attele, Y. P. Zhou, J. T. Xie et al., “Antidiabetic effects of Panax ginseng berry extract and the identification of an effective component,” Diabetes, vol. 51, no. 6, pp. 1851–1858, 2002. View at Google Scholar · View at Scopus
  4. A. Cashen, S. Lopez, F. Gao et al., “A phase II Study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with hodgkin lymphoma,” Biology of Blood and Marrow Transplantation, vol. 14, no. 11, pp. 1253–1261, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Laakso, “Insulin resistance and its impact on the approach to therapy of Type 2 diabetes,” International Journal of Clinical Practice, Supplement, no. 121, pp. 8–12, 2001. View at Google Scholar · View at Scopus
  6. R. S. Clements and D. S. H. Bell, “Complications of diabetes: prevalence, detection, current treatment, and prognosis,” American Journal of Medicine, vol. 79, no. 5, pp. 2–7, 1985. View at Google Scholar · View at Scopus
  7. J. L. Leahy, I. B. Hirsch, K. A. Peterson, and D. Schneider, “Targeting β-cell function early in the course of therapy for type 2 diabetes mellitus,” Journal of Clinical Endocrinology and Metabolism, vol. 95, no. 9, pp. 4206–4216, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Gianani, “Beta cell regeneration in human pancreas,” Seminars in Immunopathology, vol. 33, no. 1, pp. 23–27, 2011. View at Google Scholar
  9. R. A. Defronzo, “From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus,” Diabetes, vol. 58, no. 4, pp. 773–795, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Gastaldelli, E. Ferrannini, Y. Miyazaki, M. Matsuda, A. Mari, and R. A. DeFronzo, “Thiazolidinediones improve β-cell function in type 2 diabetic patients,” American Journal of Physiology, vol. 292, no. 3, pp. E871–E883, 2007. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Tourrel, D. Bailbe, M. Lacorne, M. J. Meile, M. Kergoat, and B. Portha, “Persistent improvement of type 2 diabetes in the Goto-Kakizaki rat model by expansion of the β-cell mass during the prediabetic period with glucagon-like peptide-1 or exendin-4,” Diabetes, vol. 51, no. 5, pp. 1443–1452, 2002. View at Google Scholar · View at Scopus
  12. C. Tourrel, D. Bailbé, M. J. Meile, M. Kergoat, and B. Portha, “Glucagon-Like peptide-1 and exendin-4 stimulate β-cell neogenesis in streptozotocin-treated newborn rats resulting in persistently improved glucose homeostasis at adult age,” Diabetes, vol. 50, no. 7, pp. 1562–1570, 2001. View at Google Scholar · View at Scopus
  13. M. Szabat, F. C. Lynn, B. G. Hoffman et al., “Maintenance of beta-cell maturity and plasticity in the adult pancreas: developmental biology concepts in adult physiology,” Diabetes, vol. 61, no. 6, pp. 1365–1371, 2012. View at Google Scholar
  14. A. M. Ackermann and M. Gannon, “Molecular regulation of pancreatic β-cell mass development, maintenance, and expansion,” Journal of Molecular Endocrinology, vol. 38, no. 1-2, pp. 193–206, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. A. A. Tahrani, C. J. Bailey, S. Del Prato, and A. H. Barnett, “Management of type 2 diabetes: new and future developments in treatment,” The Lancet, vol. 378, no. 9786, pp. 182–197, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. J. F. Tanti and J. Jager, “Cellular mechanisms of insulin resistance: role of stress-regulated serine kinases and insulin receptor substrates (IRS) serine phosphorylation,” Current Opinion in Pharmacology, vol. 9, no. 6, pp. 753–762, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. D. Jones, “Diabetes field cautiously upbeat despite possible setback for leading SGLT2 inhibitor,” Nature Reviews Drug Discovery, vol. 10, no. 9, pp. 645–646, 2011. View at Google Scholar
  18. G. Encina, F. Ezquer, P. Conget, and Y. Israel, “Insulin is secreted upon glucose stimulation by both gastrointestinal enteroendocrine K-cells and L-cells engineered with the preproinsulin gene,” Biological Research, vol. 44, no. 3, pp. 301–305, 2011. View at Google Scholar
  19. R. E. Pratley and M. Gilbert, “Targeting incretins in type 2 diabetes: role of GLP-1 receptor agonists and DPP-4 inhibitors,” Review of Diabetic Studies, vol. 5, no. 2, pp. 73–94, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Hlebowicz, A. Hlebowicz, S. Lindstedt et al., “Effects of 1 and 3 g cinnamon on gastric emptying, satiety, and postprandial blood glucose, insulin, glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and ghrelin concentrations in healthy subjects,” American Journal of Clinical Nutrition, vol. 89, no. 3, pp. 815–821, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Nauck, F. Stockmann, R. Ebert, and W. Creutzfeldt, “Reduced incretin effect in Type 2 (non-insulin-dependent) diabetes,” Diabetologia, vol. 29, no. 1, pp. 46–52, 1986. View at Google Scholar · View at Scopus
  22. E. Näslund, L. Backman, J. J. Holst, E. Theodorsson, and P. M. Hellström, “Importance of small bowel peptides for the improved glucose metabolism 20 years after jejunoileal bypass for obesity,” Obesity Surgery, vol. 8, no. 3, pp. 253–260, 1998. View at Publisher · View at Google Scholar · View at Scopus
  23. E. Muscelli, A. Mari, A. Casolaro et al., “Separate impact of obesity and glucose tolerance on the incretin effect in normal subjects and type 2 diabetic patients,” Diabetes, vol. 57, no. 5, pp. 1340–1348, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Hansen, C. F. Deacon, C. Ørskov, and J. J. Holst, “Glucagon-like peptide-1-(7–36)amide is transformed to glucagon-like peptide-1-(9–36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine,” Endocrinology, vol. 140, no. 11, pp. 5356–5363, 1999. View at Google Scholar · View at Scopus
  25. J. J. Holst and C. F. Deacon, “Glucagon-like peptide-1 mediates the therapeutic actions of DPP-IV inhibitors,” Diabetologia, vol. 48, no. 4, pp. 612–615, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. K. K. Nori Janosz, K. C. Zalesin, W. M. Miller, and P. A. McCullough, “Treating type 2 diabetes: incretin mimetics and enhancers,” Therapeutic Advances in Cardiovascular Disease, vol. 3, no. 5, pp. 387–395, 2009. View at Publisher · View at Google Scholar · View at Scopus
  27. M. Marre and A. Penfornis, “GLP-1 receptor agonists today,” Diabetes Research and Clinical Practice, vol. 93, no. 3, pp. 317–327, 2011. View at Google Scholar
  28. A. J. Krentz and C. J. Bailey, “Oral antidiabetic agents: current role in type 2 diabetes mellitus,” Drugs, vol. 65, no. 3, pp. 385–411, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. J. M. Egan, A. Bulotta, H. Hui, and R. Perfetti, “GLP-1 receptor agonists are growth and differentiation factors for pancreatic islet beta cells,” Diabetes/Metabolism Research and Reviews, vol. 19, no. 2, pp. 115–123, 2003. View at Publisher · View at Google Scholar · View at Scopus
  30. D. G. Parkes, K. F. Mace, and M. E. Trautmann, “Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1,” Expert Opinion on Drug Discovery, vol. 8, no. 2, pp. 219–244, 2013. View at Publisher · View at Google Scholar
  31. H. C. S. Howlett and C. J. Bailey, “A risk-benefit assessment of metformin in type 2 diabetes mellitus,” Drug Safety, vol. 20, no. 6, pp. 489–503, 1999. View at Publisher · View at Google Scholar · View at Scopus
  32. J. Q. Purnell and C. Weyer, “Weight effect of current and experimental drugs for diabetes mellitus: from promotion to alleviation of obesity,” Treatments in Endocrinology, vol. 2, no. 1, pp. 33–47, 2003. View at Publisher · View at Google Scholar · View at Scopus
  33. B. B. Zhang and D. E. Moller, “New approaches in the treatment of type 2 diabetes,” Current Opinion in Chemical Biology, vol. 4, no. 4, pp. 461–467, 2000. View at Google Scholar
  34. E. Basch, C. Ulbricht, G. Kuo, P. Szapary, and M. Smith, “Therapeutic applications of fenugreek,” Alternative Medicine Review, vol. 8, no. 1, pp. 20–27, 2003. View at Google Scholar · View at Scopus
  35. R. Kaur, M. Afzal, I. Kazmi et al., “Polypharmacy (herbal and synthetic drug combination): a novel approach in the treatment of type-2 diabetes and its complications in rats,” Journal of Natural Medicines, 2012. View at Publisher · View at Google Scholar
  36. R. J. Marles and N. R. Farnsworth, “Antidiabetic plants and their active constituents,” Phytomedicine, vol. 2, no. 2, pp. 137–189, 1995. View at Google Scholar · View at Scopus
  37. M. Habeck, “Diabetes treatments get sweet help from nature,” Nature Medicine, vol. 9, no. 10, p. 1228, 2003. View at Google Scholar · View at Scopus
  38. J. Singh, E. Cumming, G. Manoharan, H. Kalasz, and E. Adeghate, “Medicinal chemistry of the anti-diabetic effects of momordica charantia: active constituents and modes of actions,” Open Medicinal Chemistry Journal, vol. 5, supplement 2, pp. 70–77, 2011. View at Google Scholar
  39. A. Y. Oubré, T. J. Carlson, S. R. King, and G. M. Reaven, “From plant to patient: an ethnomedical approach to the identification of new drugs for the treatment of NIDDM,” Diabetologia, vol. 40, no. 5, pp. 614–617, 1997. View at Publisher · View at Google Scholar · View at Scopus
  40. C. Weidner, J. C. de Groot, A. Prasad et al., “Amorfrutins are potent antidiabetic dietary natural products,” Proceedings of the National Academy of Sciences of the United States of America, vol. 109, no. 19, pp. 7257–7262, 2012. View at Google Scholar
  41. S. Kim, H. Jwa, Y. Yanagawa, and T. Park, “Extract from Dioscorea batatas ameliorates insulin resistance in mice fed a high-fat diet,” Journal of Medicinal Food, vol. 15, no. 6, pp. 527–534, 2012. View at Google Scholar
  42. B. H. Lee, W. H. Hsu, and T. M. Pan, “Inhibitory effects of dioscorea polysaccharide on TNF-α-induced insulin resistance in mouse FL83B cells,” Journal of Agricultural and Food Chemistry, vol. 59, no. 10, pp. 5279–5285, 2011. View at Publisher · View at Google Scholar · View at Scopus
  43. J. H. Hsu, Y. C. Wu, I. M. Liu, and J. T. Cheng, “Dioscorea as the principal herb of Die-Huang-Wan, a widely used herbal mixture in China, for improvement of insulin resistance in fructose-rich chow-fed rats,” Journal of Ethnopharmacology, vol. 112, no. 3, pp. 577–584, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. X. Gao, B. Li, H. Jiang, F. Liu, D. Xu, and Z. Liu, “Dioscorea opposita reverses dexamethasone induced insulin resistance,” Fitoterapia, vol. 78, no. 1, pp. 12–15, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. M. H. Grace, D. M. Ribnicky, P. Kuhn et al., “Hypoglycemic activity of a novel anthocyanin-rich formulation from lowbush blueberry,” Vaccinium Angustifolium Aiton Phytomedicine, vol. 16, no. 5, pp. 406–415, 2009. View at Publisher · View at Google Scholar · View at Scopus
  46. Y. Liu, D. Wang, D. Zhang et al., “Inhibitory effect of blueberry polyphenolic compounds on oleic acid-induced hepatic steatosis in vitro,” Journal of Agricultural and Food Chemistry, vol. 59, no. 22, pp. 12254–12263, 2011. View at Google Scholar
  47. A. J. Stull, K. C. Cash, W. D. Johnson, C. M. Champagne, and W. T. Cefalu, “Bioactives in blueberries improve insulin sensitivity in obese, insulin-resistant men and women,” Journal of Nutrition, vol. 140, no. 10, pp. 1764–1768, 2010. View at Publisher · View at Google Scholar · View at Scopus
  48. M. Liu, K. Wu, X. Mao, Y. Wu, and J. Ouyang, “Astragalus polysaccharide improves insulin sensitivity in KKAy mice: regulation of PKB/GLUT4 signaling in skeletal muscle,” Journal of Ethnopharmacology, vol. 127, no. 1, pp. 32–37, 2010. View at Publisher · View at Google Scholar · View at Scopus
  49. X. Q. Mao, F. Yu, N. Wang et al., “Hypoglycemic effect of polysaccharide enriched extract of Astragalus membranaceus in diet induced insulin resistant C57BL/6J mice and its potential mechanism,” Phytomedicine, vol. 16, no. 5, pp. 416–425, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. M. Zhao, Z. F. Zhang, Y. Ding, J. B. Wang, and Y. Li, “Astragalus polysaccharide improves palmitate-induced insulin resistance by inhibiting PTP1B and NF-kappaB in C2C12 myotubes,” Molecules, vol. 17, no. 6, pp. 7083–7092, 2012. View at Google Scholar
  51. Y. Wu, J. P. Ou-Yang, K. Wu, Y. Wang, Y. F. Zhou, and C. Y. Wen, “Hypoglycemic effect of Astragalus polysaccharide and its effect on PTP1B,” Acta Pharmacologica Sinica, vol. 26, no. 3, pp. 345–352, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. S. Park, D. S. Kim, and S. Kang, “Gastrodia elata Blume water extracts improve insulin resistance by decreasing body fat in diet-induced obese rats: vanillin and 4-hydroxybenzaldehyde are the bioactive candidates,” European Journal of Nutrition, vol. 50, no. 2, pp. 107–118, 2011. View at Publisher · View at Google Scholar · View at Scopus
  53. J. Li, T. Liu, L. Wang et al., “Antihyperglycemic and antihyperlipidemic action of cinnamaldehyde in C57BLKS/J db/db mice,” Journal of Traditional Chinese Medicine, vol. 32, no. 3, pp. 446–452, 2012. View at Google Scholar
  54. T. Uemura, S. Hirai, N. Mizoguchi et al., “Diosgenin present in fenugreek improves glucose metabolism by promoting adipocyte differentiation and inhibiting inflammation in adipose tissues,” Molecular Nutrition and Food Research, vol. 54, no. 11, pp. 1596–1608, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. D. Puri, K. M. Prabhu, and P. S. Murthy, “Mechanism of action of a hypoglycemic principle isolated from fenugreek seeds,” Indian Journal of Physiology and Pharmacology, vol. 46, no. 4, pp. 457–462, 2002. View at Google Scholar · View at Scopus
  56. J. Guo, L. Li, J. Pan et al., “Pharmacological mechanism of Semen Litchi on antagonizing insulin resistance in rats with type 2 diabetes,” Zhong Yao Cai, vol. 27, no. 6, pp. 435–438, 2004. View at Google Scholar · View at Scopus
  57. J. S. Noh, C. H. Park, and T. Yokozawa, “Treatment with oligonol, a low-molecular polyphenol derived from lychee fruit, attenuates diabetes-induced hepatic damage through regulation of oxidative stress and lipid metabolism,” British Journal of Nutrition, vol. 106, no. 7, pp. 1013–1022, 2011. View at Publisher · View at Google Scholar · View at Scopus
  58. J. S. Noh, H. Y. Kim, C. H. Park, H. Fujii, and T. Yokozawa, “Hypolipidaemic and antioxidative effects of oligonol, a low-molecular-weight polyphenol derived from lychee fruit, on renal damage in type 2 diabetic mice,” British Journal of Nutrition, vol. 104, no. 8, pp. 1120–1128, 2010. View at Publisher · View at Google Scholar · View at Scopus
  59. S. Sasidharan, V. Sumathi, N. R. Jegathambigai, and L. Y. Latha, “Antihyperglycaemic effects of ethanol extracts of Carica papaya and Pandanus amaryfollius leaf in streptozotocin-induced diabetic mice,” Natural Product Research, vol. 25, no. 20, pp. 1982–1987, 2011. View at Google Scholar
  60. M. Kawakami, A. Hirayama, K. Tsuchiya, H. Ohgawara, M. Nakamura, and K. Umezawa, “Promotion of β-cell differentiation by the alkaloid conophylline in porcine pancreatic endocrine cells,” Biomedicine and Pharmacotherapy, vol. 64, no. 3, pp. 226–231, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. T. Kodera, S. Yamada, Y. Yamamoto et al., “Administration of conophylline and betacellulin-δ4 increases the β-cell mass in neonatal streptozotocin-treated rats,” Endocrine Journal, vol. 56, no. 6, pp. 799–806, 2009. View at Publisher · View at Google Scholar · View at Scopus
  62. T. Ogata, L. Li, S. Yamada et al., “Promotion of β-cell differentiation by conophylline in fetal and neonatal rat pancreas,” Diabetes, vol. 53, no. 10, pp. 2596–2602, 2004. View at Publisher · View at Google Scholar · View at Scopus
  63. R. Saito, S. Yamada, Y. Yamamoto et al., “Conophylline suppresses pancreatic stellate cells and improves islet fibrosis in Goto-Kakizaki rats,” Endocrinology, vol. 153, no. 2, pp. 621–630, 2012. View at Google Scholar
  64. Y. Zhang, J. Cai, H. Ruan, H. Pi, and J. Wu, “Antihyperglycemic activity of kinsenoside, a high yielding constituent from Anoectochilus roxburghii in streptozotocin diabetic rats,” Journal of Ethnopharmacology, vol. 114, no. 2, pp. 141–145, 2007. View at Publisher · View at Google Scholar · View at Scopus
  65. P. Subash-Babu, S. Ignacimuthu, P. Agastian, and B. Varghese, “Partial regeneration of β-cells in the islets of Langerhans by Nymphayol a sterol isolated from Nymphaea stellata (Willd.) flowers,” Bioorganic and Medicinal Chemistry, vol. 17, no. 7, pp. 2864–2870, 2009. View at Publisher · View at Google Scholar · View at Scopus
  66. H. F. Huseini, B. Larijani, R. Heshmat et al., “The efficacy of Silybum marianum (L.) Gaertn. (silymarin) in the treatment of type II diabetes: a randomized, double-blind, placebo-controlled, clinical trial,” Phytotherapy Research, vol. 20, no. 12, pp. 1036–1039, 2006. View at Publisher · View at Google Scholar · View at Scopus
  67. S. A. R. Hussain, “Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes,” Journal of Medicinal Food, vol. 10, no. 3, pp. 543–547, 2007. View at Publisher · View at Google Scholar · View at Scopus
  68. C. Soto, R. Mena, J. Luna et al., “Silymarin induces recovery of pancreatic function after alloxan damage in rats,” Life Sciences, vol. 75, no. 18, pp. 2167–2180, 2004. View at Publisher · View at Google Scholar · View at Scopus
  69. C. Soto, J. Pérez, V. García, E. Uría, M. Vadillo, and L. Raya, “Effect of silymarin on kidneys of rats suffering from alloxan-induced diabetes mellitus,” Phytomedicine, vol. 17, no. 14, pp. 1090–1094, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. R. K. Srivastava, S. Sharma, S. Verma, B. Arora, and H. Lal, “Influence of diabetes on liver injury induced by antitubercular drugs and on silymarin hepatoprotection in rats,” Methods and Findings in Experimental and Clinical Pharmacology, vol. 30, no. 10, pp. 731–737, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. A. I. Vengerovskii, V. A. Khazanov, K. A. Eskina, and K. Y. Vasilyev, “Effects of silymarin (hepatoprotector) and succinic acid (bioenergy regulator) on metabolic disorders in experimental diabetes mellitus,” Bulletin of Experimental Biology and Medicine, vol. 144, no. 1, pp. 53–56, 2007. View at Publisher · View at Google Scholar · View at Scopus
  72. M. A. Jose, A. Abraham, and M. P. Narmadha, “Effect of silymarin in diabetes mellitus patients with liver diseases,” Journal of Pharmacology and Pharmacotherapeutics, vol. 2, no. 4, pp. 287–289, 2011. View at Google Scholar
  73. C. Soto, R. Recoba, H. Barrón, C. Alvarez, and L. Favari, “Silymarin increases antioxidant enzymes in alloxan-induced diabetes in rat pancreas,” Comparative Biochemistry and Physiology C, vol. 136, no. 3, pp. 205–212, 2003. View at Publisher · View at Google Scholar · View at Scopus
  74. C. P. Soto, B. L. Perez, L. P. Favari, and J. L. Reyes, “Prevention of alloxan-induced diabetes mellitus in the rat by silymarin,” Comparative Biochemistry and Physiology C, vol. 119, no. 2, pp. 125–129, 1998. View at Publisher · View at Google Scholar · View at Scopus
  75. R. P. Ubillas, C. D. Mendez, S. D. Jolad et al., “Antihyperglycemic acetylenic glucosides from Bidens pilosa,” Planta Medica, vol. 66, no. 1, pp. 82–83, 2000. View at Google Scholar · View at Scopus
  76. S. C. Chien, P. H. Young, Y. J. Hsu et al., “Anti-diabetic properties of three common Bidens pilosa variants in Taiwan,” Phytochemistry, vol. 70, no. 10, pp. 1246–1254, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. K. M. Ramkumar, A. S. Lee, K. Krishnamurthi et al., “Gymnema montanum H. Protects against alloxan-induced oxidative stress and apoptosis in pancreatic β-cells,” Cellular Physiology and Biochemistry, vol. 24, no. 5-6, pp. 429–440, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Al-Romaiyan, A. J. King, S. J. Persaud, and P. M. Jones, “A novel extract of Gymnema sylvestre improves glucose tolerance in vivo and stimulates insulin secretion and synthesis in vitro,” Phytotherapy Research, vol. 24, no. 9, pp. 1370–1376.
  79. A. Al-Romaiyan, B. Liu, H. Asare-Anane et al., “A novel Gymnema sylvestre extract stimulates insulin secretion from human islets in vivo and in vitro,” Phytotherapy Research, vol. 24, no. 9, pp. 1370–1376, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. P. D. Cani, C. A. Daubioul, B. Reusens, C. Remacle, G. Catillon, and N. M. Delzenne, “Involvement of endogenous glucagon-like peptide-1 (7–36) amide on glycaemia-lowering effect of oligofructose in streptozotocin-treated rats,” Journal of Endocrinology, vol. 185, no. 3, pp. 457–465, 2005. View at Publisher · View at Google Scholar · View at Scopus
  81. N. N. Kok, L. M. Morgan, C. M. Williams, M. B. Roberfroid, J. P. Thissen, and N. M. Delzenne, “Insulin, glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide and insulin-like growth factor I as putative mediators of the hypolipidemic effect of oligofructose in rats,” Journal of Nutrition, vol. 128, no. 7, pp. 1099–1103, 1998. View at Google Scholar · View at Scopus
  82. J. E. Urías-Silvas, P. D. Cani, E. Delmée, A. Neyrinck, M. G. López, and N. M. Delzenne, “Physiological effects of dietary fructans extracted from Agave tequilana Gto. and Dasylirion spp,” British Journal of Nutrition, vol. 99, no. 2, pp. 254–261, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. A. S. Rocca, J. Lagreca, J. Kalitsky, and P. L. Brubaker, “Monounsaturated fatty acid diets improve glycemic tolerance through increased secretion of glucagon-like peptide-1,” Endocrinology, vol. 142, no. 3, pp. 1148–1155, 2001. View at Publisher · View at Google Scholar · View at Scopus
  84. P. G. Prieto, J. Cancelas, M. L. Villanueva-Peñacarrillo, I. Valverde, and W. J. Malaisse, “Effects of an olive oil-enriched diet on plasma GLP-1 concentration and intestinal content, plasma insulin concentration, and glucose tolerance in normal rats,” Endocrine, vol. 26, no. 2, pp. 107–115, 2005. View at Publisher · View at Google Scholar · View at Scopus
  85. C. Thomsen, H. Storm, J. J. Holst, and K. Hermansen, “Differential effects of saturated and monounsaturated fats on postprandial lipemia and glucagon-like peptide 1 responses in patients with type 2 diabetes,” American Journal of Clinical Nutrition, vol. 77, no. 3, pp. 605–611, 2003. View at Google Scholar · View at Scopus
  86. D. Gentilcore, R. Chaikomin, K. L. Jones et al., “Effects of fat on gastric emptying of and the glycemic, insulin, and incretin responses to a carbohydrate meal in type 2 diabetes,” Journal of Clinical Endocrinology and Metabolism, vol. 91, no. 6, pp. 2062–2067, 2006. View at Publisher · View at Google Scholar · View at Scopus
  87. T. Takahashi and M. Miyazawa, “Potent alpha-glucosidase inhibitors from safflower (Carthamus tinctorius L.) seed,” Phytotherapy Research, vol. 26, no. 5, pp. 722–726, 2012. View at Google Scholar
  88. F. Akar, M. B. Pektas, C. Tufan et al., “Resveratrol shows vasoprotective effect reducing oxidative stress without affecting metabolic disturbances in insulin-dependent diabetes of rabbits,” Cardiovascular Drugs and Therapy, vol. 25, no. 2, pp. 119–131, 2011. View at Publisher · View at Google Scholar · View at Scopus
  89. C. Chen, Y. Zhang, and C. Huang, “Berberine inhibits PTP1B activity and mimics insulin action,” Biochemical and Biophysical Research Communications, vol. 397, no. 3, pp. 543–547, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. H. W. Jeong, K. C. Hsu, J. W. Lee et al., “Berberine suppresses proinflammatory responses through AMPK activation in macrophages,” American Journal of Physiology, vol. 296, no. 4, pp. E955–E964, 2009. View at Publisher · View at Google Scholar · View at Scopus
  91. W. S. Kim, Y. S. Lee, S. H. Cha et al., “Berberine improves lipid dysregulation in obesity by controlling central and peripheral AMPK activity,” American Journal of Physiology, vol. 296, no. 4, pp. E812–E819, 2009. View at Publisher · View at Google Scholar · View at Scopus
  92. Y. S. Lee, W. S. Kim, K. H. Kim et al., “Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states,” Diabetes, vol. 55, no. 8, pp. 2256–2264, 2006. View at Publisher · View at Google Scholar · View at Scopus
  93. J. Han, H. Lin, and W. Huang, “Modulating gut microbiota as an anti-diabetic mechanism of berberine,” Medical Science Monitor, vol. 17, no. 7, pp. RA164–RA167, 2011. View at Google Scholar · View at Scopus
  94. H. Dong, N. Wang, L. Zhao, and F. Lu, “Berberine in the treatment of type 2 diabetes mellitus: a systemic review and meta-analysis,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 591654, 12 pages, 2012. View at Publisher · View at Google Scholar
  95. J. T. Hwang, I. J. Park, J. I. Shin et al., “Genistein, EGCG, and capsaicin inhibit adipocyte differentiation process via activating AMP-activated protein kinase,” Biochemical and Biophysical Research Communications, vol. 338, no. 2, pp. 694–699, 2005. View at Publisher · View at Google Scholar · View at Scopus
  96. D. X. Gram, B. Ahrén, I. Nagy et al., “Capsaicin-sensitive sensory fibers in the islets of Langerhans contribute to defective insulin secretion in Zucker diabetic rat, an animal model for some aspects of human type 2 diabetes,” European Journal of Neuroscience, vol. 25, no. 1, pp. 213–223, 2007. View at Publisher · View at Google Scholar · View at Scopus
  97. W. K. Lee, S. T. Kao, L. M. Liu, and J. T. Cheng, “Ginsenoside Rh2 is one of the active principles of Panax ginseng root to improve insulin sensitivity in fructose-rich chow-fed rats,” Hormone and Metabolic Research, vol. 39, no. 5, pp. 347–354, 2007. View at Publisher · View at Google Scholar · View at Scopus
  98. W. C. S. Cho, W. S. Chung, S. K. W. Lee, A. W. N. Leung, C. H. K. Cheng, and K. K. M. Yue, “Ginsenoside Re of Panax ginseng possesses significant antioxidant and antihyperlipidemic efficacies in streptozotocin-induced diabetic rats,” European Journal of Pharmacology, vol. 550, no. 1–3, pp. 173–179, 2006. View at Publisher · View at Google Scholar · View at Scopus
  99. J. Wickenberg, S. L. Ingemansson, and J. Hlebowicz, “Effects of Curcuma longa (turmeric) on postprandial plasma glucose and insulin in healthy subjects,” Nutrition Journal, vol. 9, no. 1, article 43, 2010. View at Publisher · View at Google Scholar · View at Scopus
  100. P. C. Lekshmi, R. Arimboor, P. S. Indulekha, and A. N. Menon, “Turmeric (Curcuma longa L.) volatile oil inhibits key enzymes linked to type 2 diabetes,” International Journal of Food Sciences and Nutrition, vol. 63, no. 7, pp. 832–834, 2012. View at Google Scholar
  101. G. M. Hussein, H. Matsuda, S. Nakamura et al., “Protective and ameliorative effects of mate (Ilex paraguariensis) on metabolic syndrome in TSOD mice,” Phytomedicine, vol. 19, no. 1, pp. 88–97, 2011. View at Google Scholar
  102. D. Chakraborty, A. Mukherjee, S. Sikdar et al., “[6]-Gingerol isolated from ginger attenuates sodium arsenite induced oxidative stress and plays a corrective role in improving insulin signaling in mice,” Toxicology Letters, vol. 210, no. 1, pp. 34–43, 2012. View at Google Scholar
  103. Y. Li, V. H. Tran, C. C. Duke, and B. D. Roufogalis, “Preventive and protective properties of Zingiber officinale (ginger) in diabetes mellitus, diabetic complications, and associated lipid and other metabolic disorders: a brief review,” Evidence-Based Complementary and Alternative Medicine, vol. 2012, Article ID 516870, 10 pages, 2012. View at Publisher · View at Google Scholar
  104. H. Ortsater, N. Grankvist, S. Wolfram, N. Kuehn, and A. Sjoholm, “Diet supplementation with green tea extract epigallocatechin gallate prevents progression to glucose intolerance in db/db mice,” Nutrition & Metabolism, vol. 9, article 11, 2012. View at Google Scholar
  105. S. Wolfram, D. Raederstorff, M. Preller et al., “Epigallocatechin gallate supplementation alleviates diabetes in rodents,” Journal of Nutrition, vol. 136, no. 10, pp. 2512–2518, 2006. View at Google Scholar · View at Scopus
  106. M. E. Waltner-Law, X. L. Wang, B. K. Law, R. K. Hall, M. Nawano, and D. K. Granner, “Epigallocatechin gallate, a constituent of green tea, represses hepatic glucose production,” Journal of Biological Chemistry, vol. 277, no. 38, pp. 34933–34940, 2002. View at Publisher · View at Google Scholar · View at Scopus
  107. S. J. Heo, J. Y. Hwang, J. I. Choi, J. S. Han, H. J. Kim, and Y. J. Jeon, “Diphlorethohydroxycarmalol isolated from Ishige okamurae, a brown algae, a potent α-glucosidase and α-amylase inhibitor, alleviates postprandial hyperglycemia in diabetic mice,” European Journal of Pharmacology, vol. 615, no. 1–3, pp. 252–256, 2009. View at Publisher · View at Google Scholar · View at Scopus
  108. Z. Fu, E. R. Gilbert, L. Pfeiffer et al., “Genistein ameliorates hyperglycemia in a mouse model of nongenetic type 2 diabetes,” Applied Physiology, Nutrition, and Metabolism, vol. 37, no. 3, pp. 480–488, 2012. View at Google Scholar
  109. Z. Fu, W. Zhang, W. Zhen et al., “Genistein induces pancreatic β-cell proliferation through activation of multiple signaling pathways and prevents insulin-deficient diabetes in mice,” Endocrinology, vol. 151, no. 7, pp. 3026–3037, 2010. View at Publisher · View at Google Scholar · View at Scopus
  110. A. Leiherer, A. Mundlein, and H. Drexel, “Phytochemicals and their impact on adipose tissue inflammation and diabetes,” Vascular Pharmacology, vol. 58, no. 1-2, pp. 3–20, 2013. View at Google Scholar
  111. S. J. Bhathena and M. T. Velasquez, “Beneficial role of dietary phytoestrogens in obesity and diabetes,” American Journal of Clinical Nutrition, vol. 76, no. 6, pp. 1191–1201, 2002. View at Google Scholar · View at Scopus
  112. S. Park, I. S. Ahn, J. H. Kim et al., “Glyceollins, one of the phytoalexins derived from soybeans under fungal stress, enhance insulin sensitivity and exert insulinotropic actions,” Journal of Agricultural and Food Chemistry, vol. 58, no. 3, pp. 1551–1557, 2010. View at Google Scholar
  113. A. Kawano, H. Nakamura, S. I. Hata, M. Minakawa, Y. Miura, and K. Yagasaki, “Hypoglycemic effect of aspalathin, a rooibos tea component from Aspalathus linearis, in type 2 diabetic model db/db mice,” Phytomedicine, vol. 16, no. 5, pp. 437–443, 2009. View at Publisher · View at Google Scholar · View at Scopus
  114. C. J. Muller, E. Joubert, D. de Beer et al., “Acute assessment of an aspalathin-enriched green rooibos (Aspalathus linearis) extract with hypoglycemic potential,” Phytomedicine, vol. 20, no. 1, pp. 32–39, 2012. View at Google Scholar
  115. S. Jo, E. Ka, H. Lee et al., “Comparison of antioxidant potential and rat intestinal α-glucosidases inihibitory activities of quercetin, rutin, and isoquercetin,” International Journal of Applied Research in Natural Products, vol. 2, pp. 52–60, 2009. View at Google Scholar
  116. P. S. Mainzen and N. Kamalakkannan, “Rutin improves glucose homeostasis in streptozotocin diabetic tissues by altering glycolytic and gluconeogenic enzymes,” Journal of Biochemical and Molecular Toxicology, vol. 20, no. 2, pp. 96–102, 2006. View at Publisher · View at Google Scholar · View at Scopus
  117. C. C. Lee, W. H. Hsu, S. R. Shen, Y. H. Cheng, and S. C. Wu, “Fagopyrum tataricum (buckwheat) improved high-glucose-induced insulin resistance in mouse hepatocytes and diabetes in fructose-rich diet-induced mice,” Experimental Diabetes Research, vol. 2012, Article ID 375673, 10 pages, 2012. View at Publisher · View at Google Scholar
  118. N. Jong-Anurakkun, M. R. Bhandari, G. Hong, and J. Kawabata, “α-Glucosidase inhibitor from Chinese aloes,” Fitoterapia, vol. 79, no. 6, pp. 456–457, 2008. View at Publisher · View at Google Scholar · View at Scopus
  119. N. Nuraliev Yu and G. A. Avezov, “The efficacy of quercetin in alloxan diabetes,” Experimental and Clinical Pharmacology, vol. 55, no. 1, pp. 42–44, 1992. View at Google Scholar · View at Scopus
  120. G. Di Maggio and G. Ciaceri, “Effect of quercetin on blood sugar levels in alloxan diabetes,” La Rassegna di Clinica, Terapia e Scienze Affini, vol. 57, no. 1, pp. 14–16, 1958. View at Google Scholar
  121. G. M. Do, U. J. Jung, H. J. Park et al., “Resveratrol ameliorates diabetes-related metabolic changes via activation of AMP-activated protein kinase and its downstream targets in db/db mice,” Molecular Nutrition & Food Research, vol. 56, no. 8, pp. 1282–1291, 2012. View at Google Scholar
  122. D. F. Ding, N. You, X. M. Wu et al., “Resveratrol attenuates renal hypertrophy in early-stage diabetes by activating AMPK,” American Journal of Nephrology, vol. 31, no. 4, pp. 363–374, 2010. View at Publisher · View at Google Scholar · View at Scopus
  123. R. Mishra, D. Sellin, D. Radovan, A. Gohlke, and R. Winter, “Inhibiting islet amyloid polypeptide fibril formation by the red wine compound resveratrol,” ChemBioChem, vol. 10, no. 3, pp. 445–449, 2009. View at Publisher · View at Google Scholar · View at Scopus
  124. L. Vetterli, T. Brun, L. Giovannoni, D. Bosco, and P. Maechler, “Resveratrol potentiates glucose-stimulated insulin secretion in INS-1E β-cells and human islets through a SIRT1-dependent mechanism,” Journal of Biological Chemistry, vol. 286, no. 8, pp. 6049–6060, 2011. View at Publisher · View at Google Scholar · View at Scopus
  125. J. K. Bhatt, S. Thomas, and M. J. Nanjan, “Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus,” Nutrition Research, vol. 32, no. 7, pp. 537–541, 2012. View at Google Scholar
  126. J. Shearer, A. Farah, T. De Paulis et al., “Quinides of roasted coffee enhance insulin action in conscious rats,” Journal of Nutrition, vol. 133, no. 11, pp. 3529–3532, 2003. View at Google Scholar · View at Scopus
  127. J. M. Tunnicliffe and J. Shearer, “Coffee, glucose homeostasis, and insulin resistance: physiological mechanisms and mediators,” Applied Physiology, Nutrition and Metabolism, vol. 33, no. 6, pp. 1290–1300, 2008. View at Publisher · View at Google Scholar · View at Scopus
  128. T. Mae, H. Kishida, T. Nishiyama et al., “A licorice ethanolic extract with peroxisome proliferator-activated receptor-γ ligand-binding activity affects diabetes in KK-Ay mice, abdominal obesity in diet-induced obese C57BL mice and hypertension in spontaneously hypertensive rats,” Journal of Nutrition, vol. 133, no. 11, pp. 3369–3377, 2003. View at Google Scholar · View at Scopus
  129. A. Basu and T. J. Lyons, “Strawberries, blueberries, and cranberries in the metabolic syndrome: clinical perspectives,” Journal of Agricultural and Food Chemistry, vol. 60, no. 23, pp. 5687–5692, 2011. View at Google Scholar
  130. J. DeFuria, G. Bennett, K. J. Strissel et al., “Dietary blueberry attenuates whole-body insulin resistance in high fat-fed mice by reducing adipocyte death and its inflammatory sequelae,” Journal of Nutrition, vol. 139, no. 8, pp. 1510–1516, 2009. View at Publisher · View at Google Scholar · View at Scopus
  131. E. M. Seymour, I. I. Tanone, D. E. Urcuyo-Llanes et al., “Blueberry intake alters skeletal muscle and adipose tissue peroxisome proliferator-activated receptor activity and reduces insulin resistance in obese rats,” Journal of Medicinal Food, vol. 14, no. 12, pp. 1511–1518, 2011. View at Google Scholar
  132. T. Vuong, A. Benhaddou-Andaloussi, A. Brault et al., “Antiobesity and antidiabetic effects of biotransformed blueberry juice in KKA y mice,” International Journal of Obesity, vol. 33, no. 10, pp. 1166–1173, 2009. View at Publisher · View at Google Scholar · View at Scopus
  133. F. Wu and X. Chen, “A review of pharmacological study on Astragalus membranaceus (Fisch.) Bge,” Zhong Yao Cai, vol. 27, no. 3, pp. 232–234, 2004. View at Google Scholar · View at Scopus
  134. C. Li, L. Cao, and Q. Zeng, “Astragalus prevents diabetic rats from developing cardiomyopathy by downregulating angiotensin II type2 receptors' expression,” Journal of Huazhong University of Science and Technology, vol. 24, no. 4, pp. 379–384, 2004. View at Google Scholar · View at Scopus
  135. B. Qin, K. S. Panickar, and R. A. Anderson, “Cinnamon: potential role in the prevention of insulin resistance, metabolic syndrome, and type 2 diabetes,” Journal of Diabetes Science and Technology, vol. 4, no. 3, pp. 685–693, 2010. View at Google Scholar · View at Scopus
  136. H. Rafehi, K. Ververis, and T. C. Karagiannis, “Controversies surrounding the clinical potential of cinnamon for the management of diabetes,” Diabetes, Obesity and Metabolism, vol. 14, no. 6, pp. 493–499, 2012. View at Google Scholar
  137. K. Couturier, B. Qin, C. Batandier et al., “Cinnamon increases liver glycogen in an animal model of insulin resistance,” Metabolism, vol. 60, no. 11, pp. 1590–1597, 2011. View at Google Scholar
  138. B. Qin, H. D. Dawson, N. W. Schoene, M. M. Polansky, and R. A. Anderson, “Cinnamon polyphenols regulate multiple metabolic pathways involved in insulin signaling and intestinal lipoprotein metabolism of small intestinal enterocytes,” Nutrition, vol. 28, no. 11-12, pp. 1172–1179, 2012. View at Google Scholar
  139. P. Subash Babu, S. Prabuseenivasan, and S. Ignacimuthu, “Cinnamaldehyde-A potential antidiabetic agent,” Phytomedicine, vol. 14, no. 1, pp. 15–22, 2007. View at Publisher · View at Google Scholar · View at Scopus
  140. K. Pavithran, “Fenugreek in diabetes mellitus,” The Journal of the Association of Physicians of India, vol. 42, no. 7, p. 584, 1994. View at Google Scholar · View at Scopus
  141. G. Valette, Y. Sauvaire, J. C. Baccou, and G. Ribes, “Hypocholesterolaemic effect of fenugreek seeds in dogs,” Atherosclerosis, vol. 50, no. 1, pp. 105–111, 1984. View at Google Scholar · View at Scopus
  142. V. Mohan and M. Balasubramanyam, “Fenugreek and insulin resistance,” The Journal of the Association of Physicians of India, vol. 49, pp. 1055–1056, 2001. View at Google Scholar · View at Scopus
  143. A. Gupta, R. Gupta, and B. Lal, “Effect of Trigonella foenum-graecum (Fenugreek) seeds on glycaemic control and insulin resistance in type 2 diabetes mellitus : a Double Blind Placebo Controlled Study,” Journal of Association of Physicians of India, vol. 49, pp. 1057–1061, 2001. View at Google Scholar · View at Scopus
  144. H. Zhang and Y. Teng, “Effect of li ren (semen litchi) anti-diabetes pills in 45 cases of diabetes mellitus,” Journal of Traditional Chinese Medicine, vol. 6, no. 4, pp. 277–278, 1986. View at Google Scholar · View at Scopus
  145. M. Fujii, I. Takei, and K. Umezawa, “Antidiabetic effect of orally administered conophylline-containing plant extract on streptozotocin-treated and Goto-Kakizaki rats,” Biomedicine and Pharmacotherapy, vol. 63, no. 10, pp. 710–716, 2009. View at Publisher · View at Google Scholar · View at Scopus
  146. Y. C. Rui, “Advances in pharmacological studies of silymarin,” Memorias do Instituto Oswaldo Cruz, vol. 86, supplement 2, pp. 79–85, 1991. View at Google Scholar · View at Scopus
  147. M. Chandalia, A. Garg, D. Lutjohann, K. Von Bergmann, S. M. Grundy, and L. J. Brinkley, “Beneficial effects of high dietary fiber intake in patients with type 2 diabetes mellitus,” The New England Journal of Medicine, vol. 342, no. 19, pp. 1392–1398, 2000. View at Publisher · View at Google Scholar · View at Scopus
  148. P. Zimmet, K. G. M. M. Alberti, and J. Shaw, “Global and societal implications of the diabetes epidemic,” Nature, vol. 414, no. 6865, pp. 782–787, 2001. View at Publisher · View at Google Scholar · View at Scopus
  149. A. C. Thanopoulou, B. G. Karamanos, F. V. Angelico et al., “Dietary fat intake as risk factor for the development of diabetes: multinational, multicenter study of the Mediterranean Group for the Study of Diabetes (MGSD),” Diabetes Care, vol. 26, no. 2, pp. 302–307, 2003. View at Publisher · View at Google Scholar · View at Scopus
  150. C. Feinle, D. O'Donovan, S. Doran et al., “Effects of fat digestion on appetite, APD motility, and gut hormones in response to duodenal fat infusion in humans,” American Journal of Physiology, vol. 284, no. 5, pp. G798–G807, 2003. View at Google Scholar · View at Scopus
  151. S. Asgary, P. Rahimi, P. Mahzouni, and H. Madani, “Antidiabetic effect of hydroalcoholic extract of Carthamus tinctorius L. in alloxan-induced diabetic rats,” Journal of Research in Medical Sciences, vol. 17, no. 4, pp. 386–392, 2012. View at Google Scholar
  152. P. R. Vuddanda, S. Chakraborty, and S. Singh, “Berberine: a potential phytochemical with multispectrum therapeutic activities,” Expert Opinion on Investigational Drugs, vol. 19, no. 10, pp. 1297–1307, 2010. View at Publisher · View at Google Scholar · View at Scopus
  153. S. K. Kulkarni and A. Dhir, “Berberine: a plant alkaloid with therapeutic potential for central nervous system disorders,” Phytotherapy Research, vol. 24, no. 3, pp. 317–324, 2010. View at Publisher · View at Google Scholar · View at Scopus
  154. M. Imanshahidi and H. Hosseinzadeh, “Pharmacological and therapeutic effects of Berberis vulgaris and its active constituent, berberine,” Phytotherapy Research, vol. 22, no. 8, pp. 999–1012, 2008. View at Publisher · View at Google Scholar · View at Scopus
  155. C. W. Lau, X. Q. Yao, Z. Y. Chen, W. H. Ko, and Y. Huang, “Cardiovascular actions of berberine,” Cardiovascular Drug Reviews, vol. 19, no. 3, pp. 234–244, 2001. View at Google Scholar · View at Scopus
  156. A. Saxena and N. K. Vikram, “Role of selected indian plants in management of type 2 diabetes: a review,” Journal of Alternative and Complementary Medicine, vol. 10, no. 2, pp. 369–378, 2004. View at Google Scholar · View at Scopus
  157. M. S. Islam and H. Choi, “Dietary red chilli (Capsicum frutescens L.) is insulinotropic rather than hypoglycemic in type 2 diabetes model of rats,” Phytotherapy Research, vol. 22, no. 8, pp. 1025–1029, 2008. View at Publisher · View at Google Scholar · View at Scopus
  158. S. N. Yun, S. J. Moon, S. K. Ko, B. O. Im, and S. H. Chung, “Wild ginseng prevents the onset of high-fat diet induced hyperglycemia and obesity in ICR mice,” Archives of Pharmacal Research, vol. 27, no. 7, pp. 790–796, 2004. View at Google Scholar · View at Scopus
  159. K. M. Yoo, C. Lee, Y. M. Lo, and B. Moon, “The hypoglycemic effects of American red ginseng (Panax quinquefolius L.) on a diabetic mouse model,” Journal of Food Science, vol. 77, no. 7, pp. H147–H152, 2012. View at Google Scholar
  160. L. Dey, J. T. Xie, A. Wang, J. Wu, S. A. Maleckar, and C. S. Yuan, “Anti-hyperglycemic effects of ginseng: comparison between root and berry,” Phytomedicine, vol. 10, no. 6-7, pp. 600–605, 2003. View at Publisher · View at Google Scholar · View at Scopus
  161. J. T. Xie, H. H. Aung, J. A. Wu, A. S. Attele, and C. S. Yuan, “Effects of American ginseng berry extract on blood glucose levels in ob/ob mice,” American Journal of Chinese Medicine, vol. 30, no. 2-3, pp. 187–194, 2002. View at Publisher · View at Google Scholar · View at Scopus
  162. J. T. Xie, C. Z. Wang, M. Ni et al., “American ginseng berry juice intake reduces blood glucose and body weight in ob/ob mice: S: sensory and nutritive qualities of food,” Journal of Food Science, vol. 72, no. 8, pp. S590–S594, 2007. View at Publisher · View at Google Scholar · View at Scopus
  163. J. T. Xie, J. A. Wu, S. Mehendale, H. H. Aung, and C. S. Yuan, “Anti-hyperglycemic effect of the polysaccharides fraction from American ginseng berry extract in ob/ob mice,” Phytomedicine, vol. 11, no. 2-3, pp. 182–187, 2004. View at Publisher · View at Google Scholar · View at Scopus
  164. J. T. Xie, Y. P. Zhou, L. Dey et al., “Ginseng berry reduces blood glucose and body weight in db/db mice,” Phytomedicine, vol. 9, no. 3, pp. 254–258, 2002. View at Google Scholar · View at Scopus
  165. V. Vuksan, J. L. Sievenpiper, V. Y. Y. Koo et al., “American ginseng (Panax quinquefolius L.) reduces postprandial glycemia in nondiabetic subjects and subjects with type 2 diabetes mellitus,” Archives of Internal Medicine, vol. 160, no. 7, pp. 1009–1013, 2000. View at Google Scholar · View at Scopus
  166. V. Vuksan, M. K. Sung, J. L. Sievenpiper et al., “Korean red ginseng (Panax ginseng) improves glucose and insulin regulation in well-controlled, type 2 diabetes: results of a randomized, double-blind, placebo-controlled study of efficacy and safety,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 18, no. 1, pp. 46–56, 2008. View at Publisher · View at Google Scholar · View at Scopus
  167. S. Kim, B. C. Shin, M. S. Lee, H. Lee, and E. Ernst, “Red ginseng for type 2 diabetes mellitus: a systematic review of randomized controlled trials,” Chinese Journal of Integrative Medicine, vol. 17, no. 12, pp. 937–944, 2011. View at Google Scholar
  168. J. L. Sievenpiper, J. T. Arnason, E. Vidgen, L. A. Leiter, and V. Vuksan, “A systematic quantitative analysis of the literature of the high variability in ginseng (Panax spp.),” Diabetes Care, vol. 27, no. 3, pp. 839–840, 2004. View at Publisher · View at Google Scholar · View at Scopus
  169. H. J. Lee, Y. H. Lee, S. K. Park et al., “Korean red ginseng (Panax ginseng) improves insulin sensitivity and attenuates the development of diabetes in Otsuka Long-Evans Tokushima fatty rats,” Metabolism, vol. 58, no. 8, pp. 1170–1177, 2009. View at Publisher · View at Google Scholar · View at Scopus
  170. F. Chen, Y. Chen, X. Kang et al., “Anti-apoptotic function and mechanism of ginseng saponins in rattus pancreatic beta-cells,” Biological & Pharmaceutical Bulletin, vol. 35, no. 9, pp. 1568–1573, 2012. View at Google Scholar
  171. Y. K. Hye and K. Kim, “Protective effect of ginseng on cytokine-induced apoptosis in pancreatic β-cells,” Journal of Agricultural and Food Chemistry, vol. 55, no. 8, pp. 2816–2823, 2007. View at Publisher · View at Google Scholar · View at Scopus
  172. H. Y. Kim and K. Kim, “Regulation of signaling molecules associated with insulin action, insulin secretion and pancreatic beta-cell mass in the hypoglycemic effects of Korean red ginseng in Goto-Kakizaki rats,” Journal of Ethnopharmacology, vol. 142, no. 1, pp. 53–58, 2012. View at Google Scholar
  173. Z. Wu, J. Z. Luo, and L. Luo, “American ginseng modulates pancreatic beta cell activities,” Chinese Medicine, vol. 2, article 11, 2007. View at Publisher · View at Google Scholar · View at Scopus
  174. J. Z. Luo and L. Luo, “Ginseng on hyperglycemia: effects and mechanisms,” Evidence-Based Complementary and Alternative Medicine, vol. 6, no. 4, pp. 423–427, 2009. View at Google Scholar
  175. H. R. Madkor, S. W. Mansour, and G. Ramadan, “Modulatory effects of garlic, ginger, turmeric and their mixture on hyperglycaemia, dyslipidaemia and oxidative stress in streptozotocin-nicotinamide diabetic rats,” British Journal of Nutrition, vol. 105, no. 8, pp. 1210–1217, 2011. View at Google Scholar
  176. B. Meng, J. Li, and H. Cao, “Antioxidant and antiinflammatory activities of curcumin on diabetes mellitus and its complications,” Current Pharmaceutical Design, vol. 19, no. 11, pp. 2101–2113, 2013. View at Google Scholar
  177. S. Chuengsamarn, S. Rattanamongkolgul, R. Luechapudiporn, C. Phisalaphong, and S. Jirawatnotai, “Curcumin extract for prevention of type 2 diabetes,” Diabetes Care, vol. 35, no. 11, pp. 2121–2127, 2012. View at Google Scholar
  178. S. P. Weisberg, R. Leibel, and D. V. Tortoriello, “Dietary curcumin significantly improves obesity-associated inflammation and diabetes in mouse models of diabesity,” Endocrinology, vol. 149, no. 7, pp. 3549–3558, 2008. View at Publisher · View at Google Scholar · View at Scopus
  179. S. Chang, M. Vogelbaum, F. F. Lang et al., “GNOSIS: guidelines for neuro-oncology: standards for investigational studies—reporting of surgically based therapeutic clinical trials,” Journal of Neuro-Oncology, vol. 82, no. 2, pp. 211–220, 2007. View at Publisher · View at Google Scholar · View at Scopus
  180. M. D. A. Saldaña, R. S. Mohamed, M. G. Baer, and P. Mazzafera, “Extraction of purine alkaloids from mate (Ilex paraguariensis) using supercritical CO2,” Journal of Agricultural and Food Chemistry, vol. 47, no. 9, pp. 3804–3808, 1999. View at Publisher · View at Google Scholar · View at Scopus
  181. N. Bracesco, A. G. Sanchez, V. Contreras, T. Menini, and A. Gugliucci, “Recent advances on Ilex paraguariensis research: minireview,” Journal of Ethnopharmacology, vol. 136, no. 3, pp. 378–384, 2011. View at Publisher · View at Google Scholar · View at Scopus
  182. M. H. Pittler, K. Schmidt, and E. Ernst, “Adverse events of herbal food supplements for body weight reduction: systematic review,” Obesity Reviews, vol. 6, no. 2, pp. 93–111, 2005. View at Publisher · View at Google Scholar · View at Scopus
  183. M. Priya Rani, K. P. Padmakumari, B. Sankarikutty, O. Lijo Cherian, V. M. Nisha, and K. G. Raghu, “Inhibitory potential of ginger extracts against enzymes linked to type 2 diabetes, inflammation and induced oxidative stress,” International Journal of Food Sciences and Nutrition, vol. 62, no. 2, pp. 106–110, 2011. View at Publisher · View at Google Scholar · View at Scopus
  184. A. Fritsche, M. Larbig, D. Owens, and H. U. Häring, “Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study,” Diabetes, Obesity and Metabolism, vol. 12, no. 2, pp. 115–123, 2010. View at Publisher · View at Google Scholar · View at Scopus
  185. M. S. Islam and H. Choi, “Comparative effects of dietary ginger (Zingiber officinale) and garlic (Allium sativum) investigated in a type 2 diabetes model of rats,” Journal of Medicinal Food, vol. 11, no. 1, pp. 152–159, 2008. View at Publisher · View at Google Scholar · View at Scopus
  186. B. Andallu, B. Radhika, and V. Suryakantham, “Effect of aswagandha, ginger and mulberry on hyperglycemia and hyperlipidemia,” Plant Foods for Human Nutrition, vol. 58, no. 3, pp. 1–7, 2003. View at Google Scholar · View at Scopus
  187. A. Bordia, S. K. Verma, and K. C. Srivastava, “Effect of ginger (Zingiber officinale Rosc.) and fenugreek (Trigonella foenumgraecum L.) on blood lipids, blood sugar and platelet aggregation in patients with coronary artery disease,” Prostaglandins Leukotrienes and Essential Fatty Acids, vol. 56, no. 5, pp. 379–384, 1997. View at Google Scholar · View at Scopus
  188. H. Iso, C. Date, K. Wakai et al., “The relationship between green tea and total caffeine intake and risk for self-reported type 2 diabetes among Japanese adults,” Annals of Internal Medicine, vol. 144, no. 8, pp. 554–562, 2006. View at Google Scholar · View at Scopus
  189. K. Hosoda, M. F. Wang, M. L. Liao et al., “Antihyperglycemic effect of oolong tea in type 2 diabetes,” Diabetes Care, vol. 26, no. 6, pp. 1714–1718, 2003. View at Publisher · View at Google Scholar · View at Scopus
  190. Y. Hayashino, S. Fukuhara, T. Okamura, T. Tanaka, and H. Ueshima, “High oolong tea consumption predicts future risk of diabetes among Japanese male workers: a prospective cohort study,” Diabetic Medicine, vol. 28, no. 7, pp. 805–810, 2011. View at Publisher · View at Google Scholar · View at Scopus
  191. M. C. Sabu, K. Smitha, and R. Kuttan, “Anti-diabetic activity of green tea polyphenols and their role in reducing oxidative stress in experimental diabetes,” Journal of Ethnopharmacology, vol. 83, no. 1-2, pp. 109–116, 2002. View at Publisher · View at Google Scholar · View at Scopus
  192. P. J. Hale, P. M. Horrocks, A. D. Wright, M. G. Fitzgerald, M. Nattrass, and C. J. Bailey, “Xiaoke tea, a Chinese herbal treatment for diabetes mellitus,” Diabetic Medicine, vol. 6, no. 8, pp. 675–676, 1989. View at Google Scholar · View at Scopus
  193. F. Meng, A. Abedini, A. Plesner, C. B. Verchere, and D. P. Raleigh, “The Flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity,” Biochemistry, vol. 49, no. 37, pp. 8127–8133, 2010. View at Publisher · View at Google Scholar · View at Scopus
  194. L. V. Kaprel'iants, S. V. Kiselev, and E. G. Iorgacheva, “Soybean isoflavones and prospects of their therapeutic application,” Voprosy Pitaniia, vol. 72, no. 4, pp. 36–41, 2003. View at Google Scholar · View at Scopus
  195. D. Y. Kwon, S. M. Hong, J. E. Lee, S. R. Sung, and S. Park, “Long-term consumption of fermented soybean-derived Chungkookjang attenuates hepatic insulin resistance in 90% pancreatectomized diabetic rats,” Hormone and Metabolic Research, vol. 39, no. 10, pp. 752–757, 2007. View at Publisher · View at Google Scholar · View at Scopus
  196. D. Y. Kwon, J. S. Jang, S. M. Hong et al., “Long-term consumption of fermented soybean-derived Chungkookjang enhances insulinotropic action unlike soybeans in 90% pancreatectomized diabetic rats,” European Journal of Nutrition, vol. 46, no. 1, pp. 44–52, 2007. View at Publisher · View at Google Scholar · View at Scopus
  197. N. Behloul and G. Wu, “Genistein: a promising therapeutic agent for obesity and diabetes treatment,” European Journal of Pharmacology, vol. 698, no. 1–3, pp. 31–38, 2013. View at Google Scholar
  198. L. Tie, Y. An, J. Han et al., “Genistein accelerates refractory wound healing by suppressing superoxide and FoxO1/iNOS pathway in type 1 diabetes,” The Journal of Nutritional Biochemistry, vol. 24, no. 1, pp. 88–96, 2013. View at Google Scholar
  199. I. F. Benter, M. H. M. Yousif, S. M. Griffiths, M. Benboubetra, and S. Akhtar, “Epidermal growth factor receptor tyrosine kinase-mediated signalling contributes to diabetes-induced vascular dysfunction in the mesenteric bed,” British Journal of Pharmacology, vol. 145, no. 6, pp. 829–836, 2005. View at Publisher · View at Google Scholar · View at Scopus
  200. A. Nanri, T. Mizoue, Y. Takahashi et al., “Soy product and isoflavone intakes are associated with a lower risk of type 2 diabetes in overweight Japanese women,” Journal of Nutrition, vol. 140, no. 3, pp. 580–586, 2010. View at Publisher · View at Google Scholar · View at Scopus
  201. D. Haberer, M. Tasker, M. Foltz et al., “Intragastric infusion of pea-protein hydrolysate reduces test-meal size in rats more than pea protein,” Physiology & Behavior, vol. 104, no. 5, pp. 1041–1047, 2011. View at Google Scholar
  202. N. Ghannam, M. Kingston, and I. A. Al-Meshaal, “The antidiabetic activity of aloes: preliminary clinical and experimental observations,” Hormone Research, vol. 24, no. 4, pp. 288–294, 1986. View at Google Scholar · View at Scopus
  203. S. Yongchaiyudha, V. Rungpitarangsi, N. Bunyapraphatsara, and O. Chokechaijaroenporn, “Antidiabetic activity of Aloe vera L. juice. I. Clinical trial in new cases of diabetes mellitus,” Phytomedicine, vol. 3, no. 3, pp. 241–243, 1996. View at Google Scholar · View at Scopus
  204. H. Beppu, K. Shimpo, T. Chihara et al., “Antidiabetic effects of dietary administration of Aloe arborescens Miller components on multiple low-dose streptozotocin-induced diabetes in mice: investigation on hypoglycemic action and systemic absorption dynamics of aloe components,” Journal of Ethnopharmacology, vol. 103, no. 3, pp. 468–477, 2006. View at Publisher · View at Google Scholar · View at Scopus
  205. S. Rajasekaran, K. Sivagnanam, K. Ravi, and S. Subramanian, “Hypoglycemic effect of Aloe vera gel on streptozotocin-induced diabetes in experimental rats,” Journal of Medicinal Food, vol. 7, no. 1, pp. 61–66, 2004. View at Publisher · View at Google Scholar · View at Scopus
  206. N. Bouras, Y. M. Kim, and S. E. Strelkov, “Influence of water activity and temperature on growth and mycotoxin production by isolates of Pyrenophora tritici-repentis from wheat,” International Journal of Food Microbiology, vol. 131, no. 2-3, pp. 251–255, 2009. View at Publisher · View at Google Scholar · View at Scopus
  207. Y. Y. Pérez, E. Jiménez-Ferrer, A. Zamilpa et al., “Effect of a polyphenol-rich extract from Aloe vera gel on experimentally induced insulin resistance in mice,” American Journal of Chinese Medicine, vol. 35, no. 6, pp. 1037–1046, 2007. View at Publisher · View at Google Scholar · View at Scopus
  208. P. Bansal, P. Paul, J. Mudgal et al., “Antidiabetic, antihyperlipidemic and antioxidant effects of the flavonoid rich fraction of Pilea microphylla (L.) in high fat diet/streptozotocin-induced diabetes in mice,” Experimental and Toxicologic Pathology, vol. 64, no. 6, pp. 651–658, 2012. View at Publisher · View at Google Scholar · View at Scopus
  209. O. Coskun, M. Kanter, A. Korkmaz, and S. Oter, “Quercetin, a flavonoid antioxidant, prevents and protects streptozotocin-induced oxidative stress and β-cell damage in rat pancreas,” Pharmacological Research, vol. 51, no. 2, pp. 117–123, 2005. View at Publisher · View at Google Scholar · View at Scopus
  210. J. H. Kim, M. J. Kang, H. N. Choi, S. M. Jeong, Y. M. Lee, and J. I. Kim, “Quercetin attenuates fasting and postprandial hyperglycemia in animal models of diabetes mellitus,” Nutrition Research and Practice, vol. 5, no. 2, pp. 107–111, 2011. View at Publisher · View at Google Scholar · View at Scopus
  211. Y. Q. Li, F. C. Zhou, F. Gao, J. S. Bian, and F. Shan, “Comparative evaluation of quercetin, isoquercetin and rutin as inhibitors of α-glucosidase,” Journal of Agricultural and Food Chemistry, vol. 57, no. 24, pp. 11463–11468, 2009. View at Publisher · View at Google Scholar · View at Scopus
  212. K. Szkudelska and T. Szkudelski, “Resveratrol, obesity and diabetes,” European Journal of Pharmacology, vol. 635, no. 1–3, pp. 1–8, 2010. View at Publisher · View at Google Scholar · View at Scopus
  213. G. Ramadori, L. Gautron, T. Fujikawa, C. R. Vianna, J. K. Elmquist, and R. Coppari, “Central administration of resveratrol improves diet-induced diabetes,” Endocrinology, vol. 150, no. 12, pp. 5326–5333, 2009. View at Publisher · View at Google Scholar · View at Scopus
  214. P. Aribal-Kocatürk, G. Özelçi Kavas, and D. Iren Büyükkaǧnici, “Pretreatment effect of resveratrol on streptozotocin-induced diabetes in rats,” Biological Trace Element Research, vol. 118, no. 3, pp. 244–249, 2007. View at Publisher · View at Google Scholar · View at Scopus
  215. Y. J. Hong, N. Kim, K. Lee et al., “Korean red ginseng (Panax ginseng) ameliorates type 1 diabetes and restores immune cell compartments,” Journal of Ethnopharmacology, vol. 144, no. 2, pp. 225–233, 2012. View at Google Scholar
  216. C. D. Venturini, S. Merlo, A. A. Souto, M. C. Fernandes, R. Gomez, and C. R. Rhoden, “Resveratrol and red wine function as antioxidants in the nervous system without cellular proliferative effects during experimental diabetes,” Oxidative Medicine and Cellular Longevity, vol. 3, no. 6, pp. 434–441, 2010. View at Publisher · View at Google Scholar · View at Scopus
  217. Z. Ungvari and A. Csiszar, “Resveratrol confers endothelial protection in insulin-dependent diabetes mellitus: editorial to: “Resveratrol shows vasoprotective effect reducing oxidative stress without affecting metabolic disturbances in insulin-dependent diabetes of rabbits” by F. Akar et al,” Cardiovascular Drugs and Therapy, vol. 25, no. 2, pp. 111–113, 2011. View at Publisher · View at Google Scholar · View at Scopus
  218. J. P. Huang, S. S. Huang, J. Y. Deng, C. C. Chang, Y. J. Day, and L. M. Hung, “Insulin and resveratrol act synergistically, preventing cardiac dysfunction in diabetes, but the advantage of resveratrol in diabetics with acute heart attack is antagonized by insulin,” Free Radical Biology and Medicine, vol. 49, no. 11, pp. 1710–1721, 2010. View at Publisher · View at Google Scholar · View at Scopus
  219. H. Zhang, B. Morgan, B. J. Potter et al., “Resveratrol improves left ventricular diastolic relaxation in type 2 diabetes by inhibiting oxidative/nitrative stress: in vivo demonstration with magnetic resonance imaging,” American Journal of Physiology, vol. 299, no. 4, pp. H985–H994, 2010. View at Publisher · View at Google Scholar · View at Scopus
  220. H. Resmi, “The combination of bortezomib and resveratrol may prevent muscle wasting in diabetes,” Medical Hypotheses, vol. 76, no. 2, pp. 291–292, 2011. View at Publisher · View at Google Scholar · View at Scopus
  221. C. R. Ku, H. J. Lee, S. K. Kim et al., “Resveratrol prevents streptozotocin-induced diabetes by inhibiting the apoptosis of pancreatic beta-cell and the cleavage of poly (ADP-ribose) polymerase,” Endocrine Journal, vol. 59, no. 2, pp. 103–109, 2012. View at Google Scholar
  222. M. Pacholec, J. E. Bleasdale, B. Chrunyk et al., “SRT1720, SRT2183, SRT1460, and resveratrol are not direct activators of SIRT1,” Journal of Biological Chemistry, vol. 285, no. 11, pp. 8340–8351, 2010. View at Publisher · View at Google Scholar · View at Scopus
  223. M. C. Haigis and D. A. Sinclair, “Mammalian sirtuins: biological insights and disease relevance,” Annual Review of Pathology, vol. 5, pp. 253–295, 2010. View at Publisher · View at Google Scholar · View at Scopus
  224. R. M. Van Dam and F. B. Hu, “Coffee consumption and risk of type 2 diabetes: a systematic review,” Journal of the American Medical Association, vol. 294, no. 1, pp. 97–104, 2005. View at Publisher · View at Google Scholar · View at Scopus
  225. N. M. Wedick, A. M. Brennan, Q. Sun et al., “Effects of caffeinated and decaffeinated coffee on biological risk factors for type 2 diabetes: a randomized controlled trial,” Nutrition Journal, vol. 10, article 93, 2011. View at Google Scholar